Tumor endothelial marker 1 is upregulated in heart after cardiac injury and participates in cardiac remodeling

Sci Rep. 2022 Jun 22;12(1):10532. doi: 10.1038/s41598-022-14567-2.

Abstract

Tumor endothelial marker 1 (TEM1) is a transmembrane glycoprotein that appears on mesenchymal lineage-derived cells during embryogenesis, but its expression greatly reduces after birth. Re-upregulation of TEM1 is found in tumor angiogenesis, organ fibrosis and wound healing indicating its potential role in tissue remodeling and repair. The expression level and function of TEM1 in adult heart are unknown. In explanted hearts from heart failure (HF) patients received cardiac transplantation, immunofluorescence staining showed TEM1 was expressed in cardiomyocytes (CMs) and cardiac fibroblasts. Bioinformatics analysis showed TEM1 upregulation in mouse heart after coronary ligation. Cardiac TEM1 expression was reconfirmed in mouse HF induced by coronary ligation or doxorubicin injection. TEM1 expression increased in cultured CMs stimulated with mechanical stretch, doxorubicin and hypoxia. Further studies showed recombinant TEM1 (rTEM1) was a functional protein that influenced cell behaviors of CMs. It directly activated Erk and Akt through interaction with PDGF receptor. TEM1lacZ/lacZ mice had less collagen deposition and worse cardiac function than wild type mice. These results indicate that TEM1 expression increases in the heart after cardiac injury and works as a functional protein that participates in cardiac remodeling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, CD* / genetics
  • Antigens, Neoplasm*
  • Doxorubicin / pharmacology
  • Heart Failure*
  • Heart Injuries*
  • Humans
  • Mice
  • Myocytes, Cardiac* / metabolism
  • Neoplasm Proteins / genetics
  • Receptors, Platelet-Derived Growth Factor
  • Ventricular Remodeling*

Substances

  • Antigens, CD
  • Antigens, Neoplasm
  • CD248 protein, human
  • Neoplasm Proteins
  • tumor endothelial marker 1, mouse
  • Doxorubicin
  • Receptors, Platelet-Derived Growth Factor